NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025 Read the press release Download: >> press_release_YM_Biosciences (.pdf 28kB) Ähnliche Beiträge
NEWS YM BioSciences’ EGFr antibody receives EU orphan drug designation through Oncoscience AG, its European partner ByOncoscience 10. August 200417. July 2025
NEWS Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy ByOncoscience 8. June 200717. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS Oncoscience AG reports marketing authorization approval for Theraloc® (Nimotuzumab) in the Ukraine ByOncoscience 13. October 200717. July 2025
NEWS Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009 ByOncoscience 9. October 200917. July 2025
NEWS Oncoscience AG and GenIlac agree on cooperation terms in Turkey ByOncoscience 7. July 201017. July 2025
